Back to Search Start Over

Palatin CEO claims 'a positive study on its face,' despite dry eye drug's primary endpoint miss.

Authors :
Armstrong, Annalee
Source :
FierceBiotech; 2/28/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Palatin has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
DRY eye syndromes
EYE
CHIEF executive officers

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
175771614

Tools

Authors Abstract Subjects Details